SENS Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -562.42% compared to Senseonics Holdings's net margin of --. Senseonics Holdings's return on equity of -445.19% beat Perspective Therapeutics's return on equity of --.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 241.01%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Senseonics Holdings, analysts believe Perspective Therapeutics is more attractive than Senseonics Holdings.

Senseonics Holdings has a beta of 0.636, which suggesting that the stock is 36.39% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are larger than Perspective Therapeutics quarterly revenues of --. Senseonics Holdings's net income of -$24M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 13.03x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

DexCom has a net margin of -562.42% compared to Senseonics Holdings's net margin of 13.54%. Senseonics Holdings's return on equity of -445.19% beat DexCom's return on equity of 30.96%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 241.01%. On the other hand DexCom has an analysts' consensus of $95.68 which suggests that it could grow by 20.51%. Given that Senseonics Holdings has higher upside potential than DexCom, analysts believe Senseonics Holdings is more attractive than DexCom.

Senseonics Holdings has a beta of 0.636, which suggesting that the stock is 36.39% less volatile than S&P 500. In comparison DexCom has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.763%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. DexCom pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than DexCom quarterly revenues of $994.2M. Senseonics Holdings's net income of -$24M is lower than DexCom's net income of $134.6M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while DexCom's PE ratio is 47.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 13.03x versus 8.39x for DexCom. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -562.42% compared to Senseonics Holdings's net margin of 10.05%. Senseonics Holdings's return on equity of -445.19% beat Electromed's return on equity of 15.62%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 241.01%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 5.67%. Given that Senseonics Holdings has higher upside potential than Electromed, analysts believe Senseonics Holdings is more attractive than Electromed.

Senseonics Holdings has a beta of 0.636, which suggesting that the stock is 36.39% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than Electromed quarterly revenues of $14.7M. Senseonics Holdings's net income of -$24M is lower than Electromed's net income of $1.5M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Electromed's PE ratio is 43.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 13.03x versus 4.88x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -562.42% compared to Senseonics Holdings's net margin of -17.98%. Senseonics Holdings's return on equity of -445.19% beat Xtant Medical Holdings's return on equity of -35.98%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 241.01%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 338.43%. Given that Xtant Medical Holdings has higher upside potential than Senseonics Holdings, analysts believe Xtant Medical Holdings is more attractive than Senseonics Holdings.

Senseonics Holdings has a beta of 0.636, which suggesting that the stock is 36.39% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Senseonics Holdings's net income of -$24M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 13.03x versus 0.60x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.